IL120902A - Couplings of polyethylene glycol-interferon a, their preparation and pharmaceutical preparations containing them - Google Patents

Couplings of polyethylene glycol-interferon a, their preparation and pharmaceutical preparations containing them

Info

Publication number: IL120902A
Authority: IL; Israel
Prior art keywords: conjugate; peg; ifna; formula; polyethylene glycol
Prior art date: 1996-05-31

Application number

IL12090297A

Other languages

English (en)

Hebrew (he)

Other versions

IL120902A0 (en

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-31

Filing date

1997-05-23

Publication date

2004-06-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21790006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL120902(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-05-23 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1997-09-30 Publication of IL120902A0 publication Critical patent/IL120902A0/xx

2004-06-20 Publication of IL120902A publication Critical patent/IL120902A/en

Links

229940079322 interferon Drugs 0.000 title claims abstract description 35
-1 Polyethylene Polymers 0.000 title claims abstract description 4
239000004698 Polyethylene Substances 0.000 title claims abstract 3
229920000573 polyethylene Polymers 0.000 title claims abstract 3
239000008194 pharmaceutical composition Substances 0.000 title claims description 7
238000002360 preparation method Methods 0.000 title description 11
229920001223 polyethylene glycol Polymers 0.000 claims abstract description 47
239000002202 Polyethylene glycol Substances 0.000 claims abstract description 44
125000003827 glycol group Chemical group 0.000 claims abstract description 5
238000011282 treatment Methods 0.000 claims description 19
238000000034 method Methods 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
201000010099 disease Diseases 0.000 claims description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
230000002519 immonomodulatory effect Effects 0.000 claims description 3
208000035473 Communicable disease Diseases 0.000 claims description 2
230000001613 neoplastic effect Effects 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims 3
238000011321 prophylaxis Methods 0.000 claims 3
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
108010050904 Interferons Proteins 0.000 description 31
102000014150 Interferons Human genes 0.000 description 31
239000003153 chemical reaction reagent Substances 0.000 description 31
210000004027 cell Anatomy 0.000 description 29
230000001028 anti-proliverative effect Effects 0.000 description 20
235000018102 proteins Nutrition 0.000 description 20
102000004169 proteins and genes Human genes 0.000 description 20
108090000623 proteins and genes Proteins 0.000 description 20
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
230000000694 effects Effects 0.000 description 18
206010028980 Neoplasm Diseases 0.000 description 17
241000699670 Mus sp. Species 0.000 description 16
230000000840 anti-viral effect Effects 0.000 description 16
241001465754 Metazoa Species 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
238000006243 chemical reaction Methods 0.000 description 8
238000000338 in vitro Methods 0.000 description 8
230000000259 anti-tumor effect Effects 0.000 description 7
238000007796 conventional method Methods 0.000 description 7
239000007943 implant Substances 0.000 description 7
230000001965 increasing effect Effects 0.000 description 7
238000007920 subcutaneous administration Methods 0.000 description 7
102100020870 La-related protein 6 Human genes 0.000 description 6
108050008265 La-related protein 6 Proteins 0.000 description 6
241000699660 Mus musculus Species 0.000 description 6
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
230000005847 immunogenicity Effects 0.000 description 6
238000011580 nude mouse model Methods 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
125000000217 alkyl group Chemical group 0.000 description 5
239000002158 endotoxin Substances 0.000 description 5
239000006167 equilibration buffer Substances 0.000 description 5
235000018977 lysine Nutrition 0.000 description 5
230000006320 pegylation Effects 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
239000005695 Ammonium acetate Substances 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
239000004472 Lysine Substances 0.000 description 4
229940043376 ammonium acetate Drugs 0.000 description 4
235000019257 ammonium acetate Nutrition 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000000872 buffer Substances 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
230000003442 weekly effect Effects 0.000 description 4
238000003556 assay Methods 0.000 description 3
201000009277 hairy cell leukemia Diseases 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
241000894007 species Species 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
208000011691 Burkitt lymphomas Diseases 0.000 description 2
241001631457 Cannula Species 0.000 description 2
208000007766 Kaposi sarcoma Diseases 0.000 description 2
241001415846 Procellariidae Species 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
229960000583 acetic acid Drugs 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
238000005277 cation exchange chromatography Methods 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012362 glacial acetic acid Substances 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229920001427 mPEG Polymers 0.000 description 2
239000002609 medium Substances 0.000 description 2
238000002559 palpation Methods 0.000 description 2
108010092853 peginterferon alfa-2a Proteins 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
239000001632 sodium acetate Substances 0.000 description 2
235000017281 sodium acetate Nutrition 0.000 description 2
239000000243 solution Substances 0.000 description 2
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
206010059313 Anogenital warts Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
108010041884 CD4 Immunoadhesins Proteins 0.000 description 1
208000000419 Chronic Hepatitis B Diseases 0.000 description 1
208000006154 Chronic hepatitis C Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
208000000907 Condylomata Acuminata Diseases 0.000 description 1
SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
239000012541 Fractogel® Substances 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
208000005176 Hepatitis C Diseases 0.000 description 1
206010022004 Influenza like illness Diseases 0.000 description 1
108010047761 Interferon-alpha Proteins 0.000 description 1
102000006992 Interferon-alpha Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
235000017858 Laurus nobilis Nutrition 0.000 description 1
241001314546 Microtis <orchid> Species 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
241000700159 Rattus Species 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
208000007660 Residual Neoplasm Diseases 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
206010065604 Suicidal behaviour Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
235000005212 Terminalia tomentosa Nutrition 0.000 description 1
244000125380 Terminalia tomentosa Species 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
241000711975 Vesicular stomatitis virus Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
229940060205 adagen Drugs 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
238000012382 advanced drug delivery Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
230000036506 anxiety Effects 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
238000011717 athymic nude mouse Methods 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
239000003729 cation exchange resin Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical class ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000012091 fetal bovine serum Substances 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
238000011010 flushing procedure Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000002672 hepatitis B Diseases 0.000 description 1
208000010710 hepatitis C virus infection Diseases 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
230000005917 in vivo anti-tumor Effects 0.000 description 1
206010022437 insomnia Diseases 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
201000002364 leukopenia Diseases 0.000 description 1
231100001022 leukopenia Toxicity 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
125000005647 linker group Chemical group 0.000 description 1
239000007788 liquid Substances 0.000 description 1
150000002669 lysines Chemical class 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
108091005573 modified proteins Proteins 0.000 description 1
102000035118 modified proteins Human genes 0.000 description 1
239000000178 monomer Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000010534 nucleophilic substitution reaction Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940002988 pegasys Drugs 0.000 description 1
NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical class OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000012552 review Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
JTESKNWFQRABFY-UHFFFAOYSA-M sodium;tetracosyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCCCCCCCOS([O-])(=O)=O JTESKNWFQRABFY-UHFFFAOYSA-M 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000013223 sprague-dawley female rat Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000004114 suspension culture Methods 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Epidemiology (AREA)
Virology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL12090297A 1996-05-31 1997-05-23 Couplings of polyethylene glycol-interferon a, their preparation and pharmaceutical preparations containing them IL120902A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US1883496P	1996-05-31	1996-05-31

Publications (2)

Publication Number	Publication Date
IL120902A0 IL120902A0 (en)	1997-09-30
IL120902A true IL120902A (en)	2004-06-20

Family

ID=21790006

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL12090297A IL120902A (en)	1996-05-31	1997-05-23	Couplings of polyethylene glycol-interferon a, their preparation and pharmaceutical preparations containing them

Country Status (47)

Country	Link
US (1)	US7201897B2 (sr)
EP (1)	EP0809996B1 (sr)
JP (1)	JP2980569B2 (sr)
KR (1)	KR100254097B1 (sr)
CN (1)	CN1088721C (sr)
AR (1)	AR008378A1 (sr)
AT (1)	ATE235920T1 (sr)
AU (1)	AU725195B2 (sr)
BG (1)	BG62273B1 (sr)
BR (1)	BR9703421A (sr)
CA (1)	CA2203480C (sr)
CO (1)	CO4950528A1 (sr)
CY (2)	CY2433B1 (sr)
CZ (1)	CZ292775B6 (sr)
DE (3)	DE809996T1 (sr)
DK (1)	DK0809996T3 (sr)
EG (1)	EG24292A (sr)
ES (1)	ES2110386T3 (sr)
GR (1)	GR970300063T1 (sr)
HR (1)	HRP970298B1 (sr)
HU (1)	HU227992B1 (sr)
IL (1)	IL120902A (sr)
IS (1)	IS1988B (sr)
LU (1)	LU91029I2 (sr)
MA (1)	MA24193A1 (sr)
MY (1)	MY117909A (sr)
NL (1)	NL300127I2 (sr)
NO (1)	NO322964B1 (sr)
NZ (1)	NZ314903A (sr)
OA (1)	OA10488A (sr)
PA (1)	PA8431001A1 (sr)
PL (1)	PL186949B1 (sr)
PT (1)	PT809996E (sr)
RS (1)	RS49533B (sr)
RU (1)	RU2180595C2 (sr)
SA (1)	SA97180030B1 (sr)
SG (1)	SG55314A1 (sr)
SI (1)	SI0809996T1 (sr)
SK (1)	SK284458B6 (sr)
SV (1)	SV1997000049A (sr)
TJ (1)	TJ328B (sr)
TN (1)	TNSN97091A1 (sr)
TR (1)	TR199700358A2 (sr)
TW (1)	TW517067B (sr)
UA (1)	UA56989C2 (sr)
UY (1)	UY24572A1 (sr)
ZA (1)	ZA974583B (sr)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5919455A (en)	1993-10-27	1999-07-06	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5951974A (en) *	1993-11-10	1999-09-14	Enzon, Inc.	Interferon polymer conjugates
US5908621A (en)	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
ES2214551T3 (es)	1995-11-02	2004-09-16	Schering Corporation	Terapia de infusion continua de citocinas a baja dosis.
US5981709A (en) *	1997-12-19	1999-11-09	Enzon, Inc.	α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) *	1997-12-19	1999-11-16	Enzon, Inc.	Substantially pure histidine-linked protein polymer conjugates
US6180096B1 (en)	1998-03-26	2001-01-30	Schering Corporation	Formulations for protection of peg-interferon alpha conjugates
CA2324467C (en) *	1998-03-26	2002-11-05	Schering Corporation	Formulations for protection of peg-interferon alpha conjugates
DE69936409T2 (de) *	1998-04-28	2008-04-17	Laboratoires Serono S.A., Coinsins	Verfahren zur schrittweise Bindung von Polyethylenglykol (PEG) an Polypeptide
DE69901321T2 (de)	1998-05-15	2002-12-12	Schering Corp., Kenilworth	Kombinationstherapie enthaltend Ribavirin und Interferon alpha bei Patienten mit chronischer Hepatitis C Infektion, die nicht antiviral vorbehandelt sind
JP3839667B2 (ja) *	1998-06-08	2006-11-01	エフ．ホフマン−ラロシュアーゲー	慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用
US6277830B1 (en) *	1998-10-16	2001-08-21	Schering Corporation	5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
IL129299A0 (en) *	1999-03-31	2000-02-17	Mor Research Applic Ltd	Monoclonal antibodies antigens and diagnosis of malignant diseases
US6605273B2 (en)	1999-04-08	2003-08-12	Schering Corporation	Renal cell carcinoma treatment
US6362162B1 (en)	1999-04-08	2002-03-26	Schering Corporation	CML Therapy
HUP0200731A3 (en) *	1999-04-08	2002-09-30	Schering Corp	Use of pegylated interferon alpha in chronic myeloid leukemia (cml) therapy
EP1535622B1 (en)	1999-04-08	2008-12-31	Schering Corporation	Melanoma therapy
US6923966B2 (en)	1999-04-08	2005-08-02	Schering Corporation	Melanoma therapy
CZ299516B6 (cs) *	1999-07-02	2008-08-20	F. Hoffmann-La Roche Ag	Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6313143B1 (en) *	1999-12-16	2001-11-06	Hoffmann-La Roche Inc.	Substituted pyrroles
HUP0203751A3 (en)	2000-01-10	2005-01-28	Maxygen Holdings Ltd Redwood C	G-csf conjugates
EP1908477A3 (en) *	2000-01-24	2008-06-11	Schering Corporation	Combination of temozolomide and pegylated interferon-alpha for treating cancer
CA2397793A1 (en) *	2000-01-24	2001-07-26	Schering Corporation	Combination of temozolomide and pegylated interferon-alpha for treating cancer
WO2001058935A2 (en)	2000-02-11	2001-08-16	Maxygen Aps	FACTOR VII OR VIIa-LIKE MOLECULES
US6476062B2 (en)	2000-03-30	2002-11-05	Schering Corporation	Chemokine receptor antagonists
US6777387B2 (en)	2000-03-31	2004-08-17	Enzon Pharmaceuticals, Inc.	Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
US6756037B2 (en)	2000-03-31	2004-06-29	Enzon, Inc.	Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6924270B2 (en)	2000-04-20	2005-08-02	Schering Corporation	Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
ES2286128T3 (es)	2000-06-30	2007-12-01	Zymogenetics, Inc.	Proteina zcyto21 tipo interferon.
CA2436623C (en) *	2001-01-30	2011-08-02	Kyowa Hakko Kogyo Co., Ltd.	Branched polyalkylene glycols
EP1366075B1 (en)	2001-02-27	2009-05-27	Maxygen Aps	New interferon beta-like molecules
DE10112825A1 (de)	2001-03-16	2002-10-02	Fresenius Kabi De Gmbh	HESylierung von Wirkstoffen in wässriger Lösung
US8048408B2 (en) *	2002-01-16	2011-11-01	Biocompatibles Uk Limited	Polymer conjugates
KR100888371B1 (ko) *	2002-01-17	2009-03-13	동아제약주식회사	가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
DE10209822A1 (de)	2002-03-06	2003-09-25	Biotechnologie Ges Mittelhesse	Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de)	2002-03-06	2003-09-25	Biotechnologie Ges Mittelhesse	Kopplung von Proteinen an ein modifiziertes Polysaccharid
ES2363205T3 (es)	2002-06-21	2011-07-26	Novo Nordisk Health Care Ag	Glicoformas del factor vii pegilado.
CN100337689C (zh)	2002-07-24	2007-09-19	弗·哈夫曼-拉罗切有限公司	聚亚烷基二醇酸加合物
US7087229B2 (en) *	2003-05-30	2006-08-08	Enzon Pharmaceuticals, Inc.	Releasable polymeric conjugates based on aliphatic biodegradable linkers
DE02020425T1 (de) *	2002-09-11	2004-07-15	Fresenius Kabi Deutschland Gmbh	Hasylierte Polypeptide, besonders hasyliertes Erythropoietin
MXPA05002594A (es)	2002-09-11	2005-05-27	Fresenius Kabi Gmbh	Derivados de polipeptidos con hidroxialquilalmidon, especialmente derivados de eritropoyetina con hidroxialquilalmidon.
AR041350A1 (es) *	2002-09-20	2005-05-11	Pharmacia Corp	Proceso para reducir los niveles de agregados de proteinas tratadas con peg
WO2004032971A1 (en)	2002-10-08	2004-04-22	Fresenius Kabi Deutschland Gmbh	Pharmaceutically active oligosaccharide conjugates
NZ540043A (en) *	2002-11-18	2007-11-30	Maxygen Inc	Isolated or recombinant Interferon-alpha polypeptides and conjugates
US7314613B2 (en)	2002-11-18	2008-01-01	Maxygen, Inc.	Interferon-alpha polypeptides and conjugates
GB0301014D0 (en) *	2003-01-16	2003-02-19	Biocompatibles Ltd	Conjugation reactions
US20050176108A1 (en) *	2003-03-13	2005-08-11	Young-Min Kim	Physiologically active polypeptide conjugate having prolonged in vivo half-life
CA2458085A1 (en)	2003-03-21	2004-09-21	F. Hoffmann-La Roche Ag	Transcriptional activity assay
WO2005014655A2 (en)	2003-08-08	2005-02-17	Fresenius Kabi Deutschland Gmbh	Conjugates of hydroxyalkyl starch and a protein
DE602004029173D1 (de)	2003-10-10	2010-10-28	Novo Nordisk As	Il-21-derivate
ES2428358T3 (es)	2003-10-17	2013-11-07	Novo Nordisk A/S	Terapia de combinación
BRPI0507169A (pt)	2004-02-02	2007-06-26	Ambrx Inc	polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
CN100355784C (zh) *	2004-02-12	2007-12-19	江苏恒瑞医药股份有限公司	聚乙二醇修饰α－干扰素1b的制备方法
EP2336192A1 (en)	2004-03-11	2011-06-22	Fresenius Kabi Deutschland GmbH	Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
WO2005113592A2 (en) *	2004-05-19	2005-12-01	Maxygen, Inc.	Interferon-alpha polypeptides and conjugates
EP1771205B1 (en)	2004-06-18	2016-10-26	Ambrx, Inc.	Novel antigen-binding polypeptides and their uses
WO2006004959A2 (en) *	2004-06-30	2006-01-12	Egen Corporation	Pegylated interferon alpha-1b
JP2008507280A (ja)	2004-07-21	2008-03-13	アンブレツクス・インコーポレイテツド	非天然コードアミノ酸を用いた生合成ポリペプチド
EP1796647B1 (en)	2004-08-12	2010-08-11	Schering Corporation	Stable pegylated interferon formulation
CA2594557C (en)	2004-12-22	2016-04-26	Ambrx, Inc.	Modified human growth hormone
US20060233740A1 (en) *	2005-03-23	2006-10-19	Bossard Mary J	Conjugates of an hGH moiety and a polymer
CA2607651A1 (en)	2005-05-18	2007-04-19	Maxygen, Inc.	Evolved interferon-alpha polypeptides
US8633300B2 (en)	2005-06-17	2014-01-21	Novo Nordisk Healthcare Ag	Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
AU2006262151A1 (en) *	2005-06-20	2007-01-04	Pepgen Corporation	Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
WO2007021297A1 (en)	2005-08-18	2007-02-22	Ambrx, Inc.	COMPOSITIONS OF tRNA AND USES THEREOF
JP4261531B2 (ja)	2005-09-06	2009-04-30	株式会社Ｎｒｌファーマ	ラクトフェリン複合体及びその製造方法
EP1951890A4 (en)	2005-11-16	2009-06-24	Ambrx Inc	PROCESSES AND COMPOSITIONS WITH NON-NATURAL AMINO ACIDS
CN101002944B (zh) *	2006-01-17	2012-07-25	中国科学院过程工程研究所	支链聚乙二醇-干扰素结合物及其制备方法
CN101002945B (zh)	2006-01-20	2012-09-05	清华大学	一种用于肿瘤治疗的新型复合物
CN100475270C (zh)	2006-01-20	2009-04-08	清华大学	一种治疗肿瘤的药物及其应用
EP2042188A4 (en)	2006-05-16	2011-11-16	Tokyo Metropolitan Org Med Res	PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF HCV INFECTION
AU2007253264A1 (en)	2006-05-24	2007-11-29	Novo Nordisk Health Care Ag	Factor IX analogues having prolonged in vivo half life
AU2007292892B9 (en)	2006-09-08	2013-02-28	Ambrx, Inc.	Hybrid suppressor tRNA for vertebrate cells
KR20090060294A (ko)	2006-09-08	2009-06-11	암브룩스, 인코포레이티드	변형된 인간 혈장 폴리펩티드 또는 Ｆｃ 스캐폴드 및 그의 용도
CN1966547B (zh) *	2006-11-06	2011-11-09	中国药科大学	双链结构的聚乙二醇衍生物的制备及其与药物分子的结合
CN101583637B (zh) *	2006-11-07	2012-08-08	帝斯曼知识产权资产管理有限公司	包含生物分子片段的氨基甲酸酯、硫代氨基甲酸酯或尿素
KR101079993B1 (ko)	2006-11-17	2011-11-04	동아제약주식회사	폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CN101219219B (zh)	2007-01-10	2013-02-13	北京普罗吉生物科技发展有限公司	包含血管抑素或其片段的复合物、其制备方法及应用
JP5515224B2 (ja)	2007-02-28	2014-06-11	日油株式会社	多分岐鎖ポリオキシアルキレン誘導体
CA2682147C (en)	2007-03-30	2017-08-08	Ambrx, Inc.	Modified fgf-21 polypeptides and their uses
CL2008002399A1 (es) *	2007-08-16	2009-01-02	Pharmaessentia Corp	Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
KR101483814B1 (ko)	2007-09-04	2015-01-16	바이오스티드 진 익스프레션 테크. 컴파니 리미티드	폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
CN101636414B (zh)	2007-09-04	2012-02-15	厦门伯赛基因转录技术有限公司	聚乙二醇修饰的干扰素α2b及其制备方法和应用
CA2703830A1 (en)	2007-11-20	2009-05-28	Ambrx, Inc.	Modified insulin polypeptides and their uses
EP2070950A1 (en)	2007-12-14	2009-06-17	Fresenius Kabi Deutschland GmbH	Hydroxyalkyl starch derivatives and process for their preparation
CN101918430A (zh) *	2008-01-18	2010-12-15	弗·哈夫曼-拉罗切有限公司	非糖基化蛋白质的纯化
LT2237799T (lt) *	2008-02-01	2019-07-25	Ascendis Pharma A/S	Provaistas, apimantis besiskaidantį linkerį
SG188143A1 (en)	2008-02-08	2013-03-28	Ambrx Inc	Modified leptin polypeptides and their uses
JP5458416B2 (ja)	2008-04-03	2014-04-02	バイオスティードジーンエクスプレッションテック．カンパニーリミテッド	二本鎖ポリエチレングリコール化成長ホルモン、その製造方法およびその使用
CA3004716C (en)	2008-04-29	2022-04-12	Ascendis Pharma Endocrinology Division A/S	Pegylated recombinant human growth hormone compounds
TW201010692A (en)	2008-06-19	2010-03-16	Public Univ Corp Nagoya City Univ	Pharmaceutical composition for treatment or prevention of hbv infection
ES2521676T3 (es)	2008-07-08	2014-11-13	Board Of Regents, The University Of Texas System	Nuevos agentes inhibidores de la proliferación y de la activación de transductores de señales y activadores de la transcripción (STATS)
EP2318029B1 (en)	2008-07-23	2017-11-01	Ambrx, Inc.	Modified bovine g-csf polypeptides and their uses
PE20110480A1 (es)	2008-09-26	2011-07-01	Ambrx Inc	Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales
US8278418B2 (en)	2008-09-26	2012-10-02	Ambrx, Inc.	Modified animal erythropoietin polypeptides and their uses
IT1399351B1 (it)	2009-06-16	2013-04-16	Fidia Farmaceutici	Procedimento per la sintesi di coniugati di glicosamminoglicani (gag) con molecole biologicamente attive, coniugati polimerici e usi relativi
US20110027229A1 (en)	2009-07-31	2011-02-03	Medtronic, Inc.	Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
KR20120106942A (ko)	2009-10-30	2012-09-27	베링거 인겔하임 인터내셔날 게엠베하	Ｂｉ２０１３３５, 인터페론 알파 및 리바비린을 포함하는 ｈｃｖ 병용 치료요법을 위한 투여 용법
EP2512450B1 (en)	2009-12-15	2018-02-07	Ascendis Pharma Endocrinology Division A/S	Dry growth hormone composition transiently linked to a polymer carrier
EA201290541A1 (ru)	2009-12-21	2013-05-30	Амбркс, Инк.	Модифицированные бычьи соматотропиновые полипептиды и их применение
JP2013515081A (ja)	2009-12-21	2013-05-02	アンブルックス，インコーポレイテッド	修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
AU2011222883B2 (en)	2010-03-05	2016-05-26	Omeros Corporation	Chimeric inhibitor molecules of complement activation
EP2569331A1 (en)	2010-05-10	2013-03-20	Perseid Therapeutics LLC	Polypeptide inhibitors of vla4
AU2011268498A1 (en)	2010-06-24	2013-01-31	Genoscience Pharma Sas	Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
RU2447083C1 (ru) *	2010-07-20	2012-04-10	Закрытое Акционерное Общество "Биокад"	НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
BR112013002532A2 (pt)	2010-08-05	2016-05-31	Hoffmann La Roche	proteína de fusão de citocina anti-viral do anticorpo anti-mhc
PE20140160A1 (es)	2010-08-17	2014-02-08	Ambrx Inc	Polipeptidos de relaxina modificados y sus usos
US9567386B2 (en)	2010-08-17	2017-02-14	Ambrx, Inc.	Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh)	2010-09-23	2015-04-11	Lilly Co Eli	牛顆粒細胞群落刺激因子及其變體之調配物
WO2012146630A1 (en)	2011-04-29	2012-11-01	F. Hoffmann-La Roche Ag	N-terminal acylated polypeptides, methods for their production and uses thereof
CN102229667A (zh) *	2011-06-03	2011-11-02	北京伟嘉人生物技术有限公司	一种聚乙二醇修饰的猪α-干扰素及其制备方法和应用
AU2012280474A1 (en)	2011-07-01	2014-01-16	Bayer Intellectual Property Gmbh	Relaxin fusion polypeptides and uses thereof
BR112014002365A2 (pt)	2011-08-03	2017-02-21	Cytheris	interleucina-7 (il-7)
JP2015509980A (ja)	2012-03-14	2015-04-02	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｈｃｖ−ｈｉｖ同時感染患者集団のｈｃｖ感染症を治療するための併用療法
WO2013143581A1 (en)	2012-03-28	2013-10-03	Boehringer Ingelheim International Gmbh	Combination therapy for treating hcv infection in specific patient subgenotype sub-population
US9738724B2 (en)	2012-06-08	2017-08-22	Sutro Biopharma, Inc.	Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP3135690A1 (en)	2012-06-26	2017-03-01	Sutro Biopharma, Inc.	Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
SI2890402T1 (sl)	2012-08-31	2019-07-31	Sutro Biopharma, Inc.	Modificirane aminokisline vsebujoče acido skupino
EA023323B1 (ru) *	2013-03-28	2016-05-31	Илья Александрович МАРКОВ	Разветвленный ацилазидный пегилирующий агент, способ его получения и способ получения пегилированного интерферона
EA021610B1 (ru) *	2013-03-28	2015-07-30	Илья Александрович МАРКОВ	Жидкое противовирусное лекарственное средство
EA022617B1 (ru) *	2013-03-28	2016-02-29	Илья Александрович МАРКОВ	Монопегилированный интерферон-альфа разветвленной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
WO2015006555A2 (en)	2013-07-10	2015-01-15	Sutro Biopharma, Inc.	Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
WO2015054658A1 (en)	2013-10-11	2015-04-16	Sutro Biopharma, Inc.	Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP2907512A1 (en)	2014-02-14	2015-08-19	Commissariat A L'energie Atomique Et Aux Energies Alternatives	Inhibitors of MMP-12 as antiviral Agents
RU2554761C1 (ru) *	2014-05-13	2015-06-27	Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии"	Противоэнтеровирусное и иммуностимулирующее средство
MX2017004947A (es)	2014-10-24	2017-06-29	Bristol Myers Squibb Co	Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos.
AU2015342908B2 (en) *	2014-11-06	2021-06-24	Pharmaessentia Corporation	Dosage regimen for pegylated interferon
KR102608645B1 (ko)	2014-11-18	2023-12-01	아센디스 파마 엔도크리놀로지 디비전 에이/에스	신규한 중합체성 hGH 프로드러그
EP4732848A3 (en)	2014-11-21	2026-07-29	Ascendis Pharma Endocrinology Division A/S	Long-acting growth hormone dosage forms
WO2017076791A1 (en)	2015-11-03	2017-05-11	F. Hoffmann-La Roche Ag	Combination therapy of an hbv capsid assembly inhibitor and an interferon
CN106749608B (zh) *	2015-11-18	2021-10-15	石药集团中奇制药技术（石家庄）有限公司	干扰素α缀合物
WO2018087345A1 (en)	2016-11-14	2018-05-17	F. Hoffmann-La Roche Ag	COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
SG10201912034UA (en)	2017-02-08	2020-02-27	Bristol Myers Squibb Co	Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
RU2678332C1 (ru)	2017-09-08	2019-01-28	Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ")	Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
KR20210057124A (ko)	2018-09-11	2021-05-20	암브룩스, 인코포레이티드	인터류킨-2 폴리펩타이드 접합체 및 그의 용도
JP2022512746A (ja)	2018-10-19	2022-02-07	アンブルックス，インコーポレイテッド	インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用
CN119455003A (zh)	2019-02-12	2025-02-18	Ambrx公司	包含抗体-tlr激动剂缀合物的组合物、方法和用途
JP7524206B2 (ja)	2019-03-04	2024-07-29	アセンディスファーマエンドクライノロジーディヴィジョンエー／エス	１日ごとのソマトロピンよりも優れた効力を有する長時間作用性成長ホルモン剤形
EP4117732A1 (en)	2020-03-11	2023-01-18	Ambrx, Inc.	Interleukin-2 polypeptide conjugates and methods of use thereof
WO2022040596A1 (en)	2020-08-20	2022-02-24	Ambrx, Inc.	Antibody-tlr agonist conjugates, methods and uses thereof
KR20230125179A (ko) *	2020-12-23	2023-08-29	재즈 파마슈티칼즈 아일랜드 리미티드	전하-차폐 융합 단백질의 정제 방법
WO2022212899A1 (en)	2021-04-03	2022-10-06	Ambrx, Inc.	Anti-her2 antibody-drug conjugates and uses thereof
US20260232768A1 (en)	2023-02-09	2026-08-13	Yanhui Xie	Treatment of atopic dermatitis with polyethylene glycol-modified interleukin 2, glucocorticoid and hyaluronic acid
WO2026043823A2 (en)	2024-08-19	2026-02-26	Sutro Biopharma, Inc.	Antibodies comprising site-specific non-natural amino acid residues, methods of preparation and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4609546A (en) *	1982-06-24	1986-09-02	Japan Chemical Research Co., Ltd.	Long-acting composition
WO1984004745A1 (fr)	1983-05-31	1984-12-06	Takeda Chemical Industries Ltd	Nouveaux polypeptides et leur utilisation
US4681848A (en) *	1982-09-22	1987-07-21	Takeda Chemical Industries, Ltd.	Novel peptide and use thereof
GB8430252D0 (en) *	1984-11-30	1985-01-09	Beecham Group Plc	Compounds
US4766106A (en) *	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
EP0229108B1 (en)	1985-06-26	1990-12-27	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3719046A1 (de) *	1987-06-06	1988-12-15	Basf Ag	Verwendung von salzen von sulfonamidcarbonsaeuren als korrosionsinhibitoren in waessrigen systemen
US5122614A (en) *	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
US5145773A (en) *	1989-05-25	1992-09-08	Sloan-Kettering Institute For Cancer Research	Method to detect sensitivity to alpha-interferon therapy
DK0400472T3 (da) *	1989-05-27	1996-05-13	Sumitomo Pharma	Fremgangsmåde til fremstilling af polyethylenglycolderivater og modificeret protein
US5238915A (en) *	1991-02-08	1993-08-24	Wakunaga Seiyaku K.K.	Aromatic composition and method for controlling aroma
US5595732A (en) *	1991-03-25	1997-01-21	Hoffmann-La Roche Inc.	Polyethylene-protein conjugates
GB9111967D0 (en)	1991-06-04	1991-07-24	Erba Carlo Spa	2,5'-nucleotide analogs as antiviral agents
US5281698A (en) *	1991-07-23	1994-01-25	Cetus Oncology Corporation	Preparation of an activated polymer ester for protein conjugation
RU2006036C1 (ru) *	1991-12-27	1994-01-15	Научно-исследовательский институт эпидемиологии и микробиологии им.Н.Ф.Гамалеи РАМН	Способ определения антигенов
ZA933926B (en)	1992-06-17	1994-01-03	Amgen Inc	Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules
US5382657A (en) *	1992-08-26	1995-01-17	Hoffmann-La Roche Inc.	Peg-interferon conjugates
US5359030A (en) *	1993-05-10	1994-10-25	Protein Delivery, Inc.	Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5919455A (en) *	1993-10-27	1999-07-06	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5643575A (en) *	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
HUT75533A (en) *	1993-11-10	1997-05-28	Schering Corp	Improved interferon polymer conjugates
DE69521880T2 (de) *	1994-02-08	2002-01-03	Amgen Inc., Thousand Oaks	Orales verabreichungssystem von chemischmodifizierten proteinen g-csf
US5824784A (en) *	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5738846A (en) *	1994-11-10	1998-04-14	Enzon, Inc.	Interferon polymer conjugates and process for preparing the same
US5932462A (en)	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW426523B (en)	1995-04-06	2001-03-21	Hoffmann La Roche	Interferon solution
CA2458085A1 (en) *	2003-03-21	2004-09-21	F. Hoffmann-La Roche Ag	Transcriptional activity assay

1997
- 1997-04-19 TW TW086105104A patent/TW517067B/zh not_active IP Right Cessation
- 1997-04-23 CA CA002203480A patent/CA2203480C/en not_active Expired - Lifetime
- 1997-05-07 RS YU17597A patent/RS49533B/sr unknown
- 1997-05-09 TR TR97/00358A patent/TR199700358A2/xx unknown
- 1997-05-12 SG SG1997001485A patent/SG55314A1/en unknown
- 1997-05-14 SA SA97180030A patent/SA97180030B1/ar unknown
- 1997-05-22 DE DE0809996T patent/DE809996T1/de active Pending
- 1997-05-22 PT PT97108261T patent/PT809996E/pt unknown
- 1997-05-22 DE DE69720320T patent/DE69720320T2/de not_active Expired - Lifetime
- 1997-05-22 AT AT97108261T patent/ATE235920T1/de active
- 1997-05-22 EP EP97108261A patent/EP0809996B1/en not_active Expired - Lifetime
- 1997-05-22 DK DK97108261T patent/DK0809996T3/da active
- 1997-05-22 ES ES97108261T patent/ES2110386T3/es not_active Expired - Lifetime
- 1997-05-22 SI SI9730506T patent/SI0809996T1/xx unknown
- 1997-05-22 DE DE2003199018 patent/DE10399018I1/de active Pending
- 1997-05-23 IL IL12090297A patent/IL120902A/en not_active IP Right Cessation
- 1997-05-26 ZA ZA974583A patent/ZA974583B/xx unknown
- 1997-05-26 NZ NZ314903A patent/NZ314903A/xx not_active IP Right Cessation
- 1997-05-27 PA PA19978431001A patent/PA8431001A1/es unknown
- 1997-05-27 EG EG46597A patent/EG24292A/xx active
- 1997-05-27 TN TNTNSN97091A patent/TNSN97091A1/fr unknown
- 1997-05-28 HU HU9700959A patent/HU227992B1/hu unknown
- 1997-05-28 SK SK673-97A patent/SK284458B6/sk not_active IP Right Cessation
- 1997-05-28 HR HR970298A patent/HRP970298B1/xx not_active IP Right Cessation
- 1997-05-28 PL PL97320251A patent/PL186949B1/pl unknown
- 1997-05-29 CO CO97029836A patent/CO4950528A1/es unknown
- 1997-05-29 AR ARP970102305A patent/AR008378A1/es active IP Right Grant
- 1997-05-29 MY MYPI97002342A patent/MY117909A/en unknown
- 1997-05-29 JP JP9139807A patent/JP2980569B2/ja not_active Expired - Lifetime
- 1997-05-29 CN CN97113049A patent/CN1088721C/zh not_active Expired - Lifetime
- 1997-05-30 OA OA70015A patent/OA10488A/fr unknown
- 1997-05-30 RU RU97108698/14A patent/RU2180595C2/ru active
- 1997-05-30 NO NO19972480A patent/NO322964B1/no not_active IP Right Cessation
- 1997-05-30 CZ CZ19971679A patent/CZ292775B6/cs not_active IP Right Cessation
- 1997-05-30 KR KR1019970022223A patent/KR100254097B1/ko not_active Expired - Lifetime
- 1997-05-30 UA UA97052543A patent/UA56989C2/uk unknown
- 1997-05-30 SV SV1997000049A patent/SV1997000049A/es not_active Application Discontinuation
- 1997-05-30 BG BG101540A patent/BG62273B1/bg unknown
- 1997-05-30 AU AU23723/97A patent/AU725195B2/en not_active Expired
- 1997-05-30 TJ TJ97000465A patent/TJ328B/xx unknown
- 1997-05-30 UY UY24572A patent/UY24572A1/es not_active IP Right Cessation
- 1997-05-30 MA MA24641A patent/MA24193A1/fr unknown
- 1997-05-30 IS IS4491A patent/IS1988B/is unknown
- 1997-06-02 BR BR9703421A patent/BR9703421A/pt not_active IP Right Cessation
1998
- 1998-01-30 GR GR970300063T patent/GR970300063T1/el unknown
2003
- 2003-02-27 US US10/377,892 patent/US7201897B2/en not_active Expired - Fee Related
- 2003-05-08 NL NL300127C patent/NL300127I2/nl unknown
- 2003-06-25 LU LU91029C patent/LU91029I2/fr unknown
2004
- 2004-03-19 CY CY0400021A patent/CY2433B1/xx unknown
2005
- 2005-04-05 CY CY200500006C patent/CY2005006I2/el unknown

Also Published As

Publication number	Publication date
IS4491A (is)	1997-12-01
EP0809996A2 (en)	1997-12-03
NZ314903A (en)	1998-10-28
KR970074791A (ko)	1997-12-10
CA2203480A1 (en)	1997-11-30
NL300127I1 (sr)	2003-07-01
JP2980569B2 (ja)	1999-11-22
SK67397A3 (en)	1997-12-10
IS1988B (is)	2005-02-15
TR199700358A3 (tr)	1997-12-21
HUP9700959A2 (hu)	1998-03-02
HK1005225A1 (en)	1998-12-31
PT809996E (pt)	2003-06-30
HUP9700959A3 (en)	1998-03-30
CA2203480C (en)	2009-06-30
EP0809996B1 (en)	2003-04-02
YU17597A (sh)	1999-07-28
PL320251A1 (en)	1997-12-08
ATE235920T1 (de)	2003-04-15
DE69720320T2 (de)	2004-06-03
DK0809996T3 (da)	2003-07-21
NO972480D0 (no)	1997-05-30
US20040030101A1 (en)	2004-02-12
DE69720320D1 (de)	2003-05-08
IL120902A0 (en)	1997-09-30
HU9700959D0 (en)	1997-07-28
EP0809996A3 (en)	1999-04-14
KR100254097B1 (ko)	2000-05-01
MY117909A (en)	2004-08-30
UA56989C2 (uk)	2003-06-16
LU91029I2 (fr)	2004-01-23
CY2005006I1 (el)	2009-11-04
ZA974583B (en)	1998-11-17
CY2433B1 (en)	2004-11-12
HRP970298A2 (en)	1998-04-30
PL186949B1 (pl)	2004-04-30
TR199700358A2 (xx)	1997-12-21
NL300127I2 (nl)	2003-09-01
CZ292775B6 (cs)	2003-12-17
UY24572A1 (es)	2000-12-29
NO322964B1 (no)	2006-12-18
TJ328B (en)	2001-12-24
CN1167777A (zh)	1997-12-17
HU227992B1 (en)	2012-08-28
SV1997000049A (es)	1998-07-09
CZ167997A3 (en)	1997-12-17
BG101540A (en)	1998-02-27
MA24193A1 (fr)	1997-12-31
CO4950528A1 (es)	2000-09-01
HRP970298B1 (en)	2003-08-31
ES2110386T3 (es)	2003-10-01
US7201897B2 (en)	2007-04-10
NO972480L (no)	1997-12-01
RS49533B (sr)	2006-12-15
AR008378A1 (es)	2000-01-19
TNSN97091A1 (fr)	2005-03-15
AU725195B2 (en)	2000-10-05
SG55314A1 (en)	1998-12-21
CY2005006I2 (el)	2009-11-04
OA10488A (fr)	2002-04-11
TJ97000465A (en)	1998-12-25
PA8431001A1 (es)	2000-05-24
BG62273B1 (bg)	1999-07-30
SK284458B6 (sk)	2005-04-01
SI0809996T1 (en)	2003-08-31
TW517067B (en)	2003-01-11
MX9704012A (es)	1997-11-29
DE10399018I1 (de)	2003-10-23
ES2110386T1 (es)	1998-02-16
CN1088721C (zh)	2002-08-07
SA97180030B1 (ar)	2005-11-12
JPH1067800A (ja)	1998-03-10
DE809996T1 (de)	1998-04-09
RU2180595C2 (ru)	2002-03-20
GR970300063T1 (en)	1998-01-30
BR9703421A (pt)	1998-09-15
AU2372397A (en)	1997-12-04
EG24292A (en)	2009-01-08

Legal Events

Date	Code	Title
2004-11-24	FF	Patent granted
2005-01-24	EXTP	Application for extension order is pending
2005-02-20	KB	Patent renewed
2005-07-25	PEL	Intention of commissioner to extend period of protection
2006-02-05	EXTG	Extension of patent term granted
2007-07-06	KB	Patent renewed
2012-02-29	MM9K	Patent not in force due to non-payment of renewal fees
2015-06-30	NE	Application for restoration - patent lapsed through non-payment of renewal fees (section 60, patents law, 5727-1967)
2018-01-31	EXP	Patent expired

Publication	Publication Date	Title
CA2203480C (en)	2009-06-30	Interferon conjugates
AU739359B2 (en)	2001-10-11	Improved interferon polymer conjugates
CA2312976C (en)	2012-06-19	Compositions comprising histidine-linked protein polymer conjugates
US20060029573A1 (en)	2006-02-09	Pegylated interferon alpha-1b
JP2003155299A (ja)	2003-05-27	Ｎ末端化学修飾タンパク質組成物および方法
HUT75533A (en)	1997-05-28	Improved interferon polymer conjugates
KR20020007296A (ko)	2002-01-26	Ｇｃｓｆ 결합체
RU2447083C1 (ru)	2012-04-10	НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ
JP5458416B2 (ja)	2014-04-02	二本鎖ポリエチレングリコール化成長ホルモン、その製造方法およびその使用
HK1005225B (en)	2003-11-14	Interferon conjugates
MXPA97004012A (en)	1998-07-03	Conjugados de interfe
KR100888371B1 (ko)	2009-03-13	가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
MXPA99011862A (es)	2000-12-06	Conjugados mejorados de polimero de interferon